In a melanoma mouse model, blocking with neutralizing antibodies HSP90α, but not HSP90β, leads to a dose-dependent decrease in MMP2 activity, blood vessel density and tumour growth [117]. This evidence concerns the gene HSP90AB1 and neoplasm.